Kalshi announced it would start taking bets on clinical trial outcomes and U.S. Food and Drug Administration (FDA) regulatory reviews, partnering with intelligence platform AppliedXL. These prediction markets are designed to make drug-development odds public, reflecting the weight of evidence rather than sponsor messaging.
Contracts available at launch include more than a dozen FDA decisions, including whether the agency will approve Gilead’s anito-cel and Summit’s ivonescimab (two of the most closely watched oncology assets).
How the markets work
Each contract specifies a named public document as its resolution source: the registered primary endpoint on ClinicalTrials.gov, the FDA approval letter, or an advisory committee vote record. AppliedXL defines the criteria for reading that document before trading opens, not after results arrive. “Clinical trial results are rarely handed to you cleanly,” said AppliedXL Co-Founder Francesco Marconi. “Resolving a market means reconciling all of that back to the primary source.”
Safeguards against insider trading
Kalshi put up several guardrails for these new markets. The pilot only covers late-stage trials, and they won’t list contracts until after enrollment is finished so they don’t mess with how doctors refer or recruit patients.
Employment verification is required for all traders, and the platform’s existing rules prohibit trading by anyone holding material nonpublic information. Kalshi CEO Tarek Mansour called drug development “one of the most important and most information-constrained industries on earth.”
What this means for the crypto world
Kalshi jumping into the biopharma scene might just be a huge deal for the whole crypto and prediction market world. The way these markets are set up (contracts tied to discrete, verifiable public documents, paired with clear resolution rules set before trading starts) offers a framework that could work for things like AI breakthroughs or even major crypto protocol updates.
Plus, this launch places the concept of “information markets” right in front of a brand-new audience, potentially driving mainstream awareness and adoption of prediction market platforms that are foundational to the Web3 space.
